DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026

---
DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026
Vote:
0 0
Previous Sanyou Bio Launches SAI-DA 1.0, the AI-Drug Accelerator
Next United Imaging Highlights uMR Jupiter 5T and uMR Ultra, along with the latest MRI advancements at ISMRM 2026

Related News

DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

DeepQure Advances Global Clinical Trials for Innovative RDN Technology

Aktiia's Continual Blood Pressure Solution Shows Comparable Results to ABPM

NOVI Health's Hybrid Care Model Closes Gap Between Clinical Trials and Real-World GLP-1 Outcomes

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

menu
menu